Physician profile
Kevin N Williams
NPI 1841687829
$647,303.47
in general payments reported to CMS, 2019-2025
20 companies · $218K in 2025
The $218K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48K · 2022: $123K · 2023: $137K · 2024: $122K · 2025: $218K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $284K · Travel and Lodging: $77K · Consulting Fee: $68K · Honoraria: $27K · Food and Beverage: $20K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $283,784.00 |
| Travel and Lodging | $77,355.18 |
| Consulting Fee | $68,331.75 |
| Honoraria | $27,352.00 |
| Food and Beverage | $19,785.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $452,484.32 | 2021-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $87,297.38 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $36,548.14 | 2022-2025 | |
| Axsome Therapeutics, INC. | $32,288.49 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20,835.53 | 2024-2025 | Caplyta |
| Alkermes, INC. | $6,264.29 | 2023-2025 | Lybalvi, Aristada |
| Acadia Pharmaceuticals INC | $3,185.30 | 2021 | |
| Supernus Pharmaceuticals, INC. | $2,617.85 | 2024 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $1,877.00 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Scientific Affairs, LLC | $1,450.00 | 2024 | |
| Biogen, INC. | $1,442.68 | 2023 | Zurzuvae |
| Lundbeck LLC | $282.72 | 2024-2025 | Rexulti |
| Theratechnologies INC. | $141.27 | 2023-2025 | Egrifta, Trogarzo |
| Sage Therapeutics, LLC | $136.67 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $111.62 | 2021-2025 | Spravato, Invega Sustenna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $90.72 | 2024-2025 | Rejoyn |
| E.R. Squibb & Sons, L.L.C. | $89.80 | 2024-2025 | Cobenfy |
| Alnylam Pharmaceuticals INC. | $79.09 | 2023 | Amvuttra |
| Almatica Pharma LLC | $57.09 | 2024-2025 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $23.51 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.